Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuel Berger

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Nature Communications|October 28, 2016
Mitochondrial function controls intestinal epithelial stemness and proliferationEmanuel Berger, Eva Rath, Detian Yuan, et al.
Parkinsonism & Related Disorders|October 18, 2019
Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patientsSarah Louise Nickels, Jonas Walter, Silvia Bolognin, et al.
NPJ Parkinson'S Disease|April 10, 2019
Modeling Parkinson's disease in midbrain-like organoidsLisa M Smits, Lydia Reinhardt, Peter Reinhardt, et al.
JAMA Psychiatry|November 29, 2016
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical TrialPatrick D McGorry, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Schizophrenia Research|March 16, 2020
Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trialSumudu Rasangi Mallawaarachchi, G Paul Amminger, John Farhall, et al.
Cell Reports|October 23, 2021
The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1Jonas Walter, Silvia Bolognin, Suresh K Poovathingal, et al.
Elife|September 27, 2021
Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processingCorrado Sandini, Daniela Zöller, Maude Schneider, et al.
Schizophrenia Bulletin Open|August 15, 2024
Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class AnalysisKelly Allott, Stefanie J Schmidt, Hok Pan Yuen, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Nature Communications|October 28, 2016
Mitochondrial function controls intestinal epithelial stemness and proliferationEmanuel Berger, Eva Rath, Detian Yuan, et al.
Parkinsonism & Related Disorders|October 18, 2019
Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patientsSarah Louise Nickels, Jonas Walter, Silvia Bolognin, et al.
NPJ Parkinson'S Disease|April 10, 2019
Modeling Parkinson's disease in midbrain-like organoidsLisa M Smits, Lydia Reinhardt, Peter Reinhardt, et al.
JAMA Psychiatry|November 29, 2016
Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical TrialPatrick D McGorry, Barnaby Nelson, Connie Markulev, et al.
Schizophrenia Research|December 19, 2018
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trialLuke K Bolt, G Paul Amminger, John Farhall, et al.
Early Intervention in Psychiatry|September 7, 2020
Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosisAlison McLaverty, Kelly A Allott, Maximus Berger, et al.
Schizophrenia Research|March 16, 2020
Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trialSumudu Rasangi Mallawaarachchi, G Paul Amminger, John Farhall, et al.
Cell Reports|October 23, 2021
The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1Jonas Walter, Silvia Bolognin, Suresh K Poovathingal, et al.
Elife|September 27, 2021
Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processingCorrado Sandini, Daniela Zöller, Maude Schneider, et al.
Schizophrenia Bulletin Open|August 15, 2024
Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class AnalysisKelly Allott, Stefanie J Schmidt, Hok Pan Yuen, et al.
Pageof 3